PMID- 21641280 OWN - NLM STAT- MEDLINE DCOM- 20120608 LR - 20181201 IS - 1532-2122 (Electronic) IS - 1462-3889 (Linking) VI - 16 IP - 2 DP - 2012 Apr TI - Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. PG - 172-84 LID - 10.1016/j.ejon.2011.05.001 [doi] AB - PURPOSE: As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib. METHOD: Focusing on the AEs we considered the most difficult to manage (hand-foot skin reaction [HFSR], diarrhoea, fatigue and mucositis/stomatitis), we reviewed the literature to identify strategies relevant to sorafenib. Given the paucity of published work, this included strategies concerning targeted agents in general. This information was supplemented by considering the wider literature relating to management of these AEs in other tumour types and similar toxicities experienced during conventional anti-cancer therapy. Together with our own experience, this information was used to compile an AE management guide to assist nurses caring for patients receiving sorafenib. RESULTS: Our collated experience suggests the most commonly reported AEs with sorafenib and other targeted agents are HFSR, diarrhoea, fatigue, rash and mucositis/stomatitis; these generally have an acute (appearing at approximately 0-1 months) or delayed onset (appearing at approximately 3 months). Most management strategies in the literature were experience-based rather than arising from controlled studies. However, strategies based on controlled studies are available for HFSR and mucositis/stomatitis. CONCLUSIONS: Evidence, especially from controlled studies, is sparse concerning management of AEs associated with sorafenib and other targeted agents in RCC/HCC. However, recommendations can be made based on the literature and clinical experience that encompasses targeted and conventional therapies, particularly in the case of non-specific toxicities e.g. diarrhoea and fatigue. CI - Copyright A(c) 2011 Elsevier Ltd. All rights reserved. FAU - Edmonds, Kim AU - Edmonds K AD - 3rd Floor Mulberry House, Fulham Road, London SW3 6JJ, UK. Kim.Edmonds@rmh.nhs.uk FAU - Hull, Diana AU - Hull D FAU - Spencer-Shaw, Andrea AU - Spencer-Shaw A FAU - Koldenhof, Jose AU - Koldenhof J FAU - Chrysou, Maria AU - Chrysou M FAU - Boers-Doets, Christine AU - Boers-Doets C FAU - Molassiotis, Alexander AU - Molassiotis A LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20110608 PL - Scotland TA - Eur J Oncol Nurs JT - European journal of oncology nursing : the official journal of European Oncology Nursing Society JID - 100885136 RN - 0 (Antineoplastic Agents) RN - 0 (Benzenesulfonates) RN - 0 (Phenylurea Compounds) RN - 0 (Pyridines) RN - 25X51I8RD4 (Niacinamide) RN - 9ZOQ3TZI87 (Sorafenib) SB - IM MH - Antineoplastic Agents/*adverse effects MH - Benzenesulfonates/*adverse effects MH - Carcinoma, Hepatocellular/drug therapy MH - Carcinoma, Renal Cell/drug therapy MH - Clinical Trials, Phase III as Topic MH - Diarrhea/chemically induced/*nursing MH - Drug Eruptions/etiology/*nursing MH - Europe MH - Fatigue/chemically induced/*nursing MH - Foot Dermatoses/chemically induced/nursing MH - Hand Dermatoses/chemically induced/nursing MH - Humans MH - Kidney Neoplasms/drug therapy MH - Liver Neoplasms/drug therapy MH - Molecular Targeted Therapy/*adverse effects MH - Mucositis/chemically induced/*nursing MH - Niacinamide/analogs & derivatives MH - Nursing Assessment/*methods MH - Phenylurea Compounds MH - Practice Guidelines as Topic MH - Pyridines/*adverse effects MH - Randomized Controlled Trials as Topic MH - Societies, Nursing MH - Sorafenib EDAT- 2011/06/07 06:00 MHDA- 2012/06/09 06:00 CRDT- 2011/06/07 06:00 PHST- 2010/10/13 00:00 [received] PHST- 2011/02/21 00:00 [revised] PHST- 2011/05/06 00:00 [accepted] PHST- 2011/06/07 06:00 [entrez] PHST- 2011/06/07 06:00 [pubmed] PHST- 2012/06/09 06:00 [medline] AID - S1462-3889(11)00083-4 [pii] AID - 10.1016/j.ejon.2011.05.001 [doi] PST - ppublish SO - Eur J Oncol Nurs. 2012 Apr;16(2):172-84. doi: 10.1016/j.ejon.2011.05.001. Epub 2011 Jun 8.